在接受3,4-甲基二氧化甲胺治疗的动物中,德克斯特罗梅索芬缓和了与中央血清素载体可用性相关的奖励缺陷
Chuang-Hsin Chiu1, Kuo-Hsing Ma2, Eagle Yi-Kung Huang3
1Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|April 8, 2024
概括
德克斯特罗梅索芬 (DM) 可能会逆转3,4-甲基二氧化甲胺 (MDMA) 对大脑中血清素输送体 (SERT) 的神经毒性作用. 在大鼠服用MDMA后,DM治疗显著恢复了SERT水平和密度.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 毒理学 毒理学 毒理学
背景情况:
- 众所周知,3,4-甲基二氧化甲胺 (MDMA) 会对神经系统产生神经毒性.
- 德克斯特罗梅索芬 (DM) 已显示出在预防MDMA诱导的血清激素缺乏症和降低药物回报方面的潜力.
- 长期使用MDMA会导致血清素载体 (SERT) 的可用性丧失.
研究的目的:
- 调查DM对MDMA诱导的神经毒性的影响.
- 评估DM对与MDMA相关的奖励和行为敏感性的影响.
- 为了确定DM是否可以逆转MDMA诱导的SERT损失.
主要方法:
- 条件化的位置偏好 (CPP) 和运动活动测试被用来评估药物奖励和行为敏感性.
- 使用4-[18F]-ADAM和免疫组织化学的正子发射断层扫描 (PET) 用于评估SERT水平和密度.
- 纵向体内PET成像追踪了随时间变化的SERT可用性.
主要成果:
- 在大鼠大脑中,MDMA显著降低了SERT结合.
- 同时使用DM和MDMA显著恢复了SERT水平,在第14天恢复率提高了23%.
- 免疫组织化学证实,在MDMA诱导的减少后,DM增加了血清纤维密度.
结论:
- 麻醉药诱导了对决策和动机至关重要的大脑区域的功能异常.
- 迪姆显示神经保护作用,逆转MDMA诱导的神经毒性.
- 用PET测量的SERT可用性与奖励系统活动有负相关性.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
227
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
227
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
469
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
469
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K